Skip to main content
Erschienen in: Medizinische Klinik - Intensivmedizin und Notfallmedizin 4/2016

09.05.2016 | Pneumonie | Leitthema

Die schwere Pneumonie auf der Intensivstation

verfasst von: Prof. Dr. T. Welte

Erschienen in: Medizinische Klinik - Intensivmedizin und Notfallmedizin | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Pneumonien haben eine hohe Morbidität und Sterblichkeit und sind für erhebliche Kosten im Gesundheitssystem verantwortlich. Mit der S3-Leitlinie zur Prävention, Diagnostik und Therapie erwachsener Patienten mit ambulant erworbener Pneumonie und der S3-Leitlinie zur Epidemiologie, Diagnostik und Therapie der nosokomialen Pneumonie stehen in Deutschland zwei evidenzbasierte Empfehlungen zur Verfügung, die als Orientierung für die Therapie dieser Erkrankungen gelten können. Auf dieser Grundlage kann ein an der spezifischen Situation des Patienten orientiertes Management durchgeführt werden.
Literatur
1.
Zurück zum Zitat Bosch CM van den, Geerlings SE, Natsch S (2015) Quality indicators to measure appropriate antibiotic use in hospitalized adults. Clin Infect Dis 60(2):281–291CrossRefPubMed Bosch CM van den, Geerlings SE, Natsch S (2015) Quality indicators to measure appropriate antibiotic use in hospitalized adults. Clin Infect Dis 60(2):281–291CrossRefPubMed
2.
Zurück zum Zitat Maschmeyer G, Carratalà J, Buchheidt D et al (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO. Ann Oncol 26(1):21–33CrossRefPubMedPubMedCentral Maschmeyer G, Carratalà J, Buchheidt D et al (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO. Ann Oncol 26(1):21–33CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Singanayagam A, Chalmers JD, Welte T (2014) Epidemiology of CAP in Europe. Eur Respir Monogr 63:1–12 Singanayagam A, Chalmers JD, Welte T (2014) Epidemiology of CAP in Europe. Eur Respir Monogr 63:1–12
4.
Zurück zum Zitat AQUA Instituts GmbH (2015) Qualitätsreport 2014. , Göttingen, S 26–30 AQUA Instituts GmbH (2015) Qualitätsreport 2014. , Göttingen, S 26–30
5.
Zurück zum Zitat Welte T, Brunkhorst F, Kuhnt E (2012) Treatment of Sepsis-Related Organ Dysfunction Reply. JAMA 308(12):1206–1207CrossRef Welte T, Brunkhorst F, Kuhnt E (2012) Treatment of Sepsis-Related Organ Dysfunction Reply. JAMA 308(12):1206–1207CrossRef
6.
Zurück zum Zitat Welte T, Dellinger RP, Ebelt H et al (2015) Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation – The CIGMA study. Respir Med 109(6):758–767CrossRefPubMed Welte T, Dellinger RP, Ebelt H et al (2015) Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation – The CIGMA study. Respir Med 109(6):758–767CrossRefPubMed
7.
Zurück zum Zitat Welte T. CIGMA – A pioneering Trial in sCAP, ISICEM 2016, 16.03.2016 Welte T. CIGMA – A pioneering Trial in sCAP, ISICEM 2016, 16.03.2016
8.
Zurück zum Zitat Kolditz M, Ewig S, Klapdor B et al (2015) Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax 70:551–558CrossRefPubMed Kolditz M, Ewig S, Klapdor B et al (2015) Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax 70:551–558CrossRefPubMed
9.
Zurück zum Zitat Ewig S, Höffken G, Kern WV et al (2016) Management of adult community-acquired pneumonia and prevention – update 2016. Pneumologie 70(3):151–200CrossRefPubMed Ewig S, Höffken G, Kern WV et al (2016) Management of adult community-acquired pneumonia and prevention – update 2016. Pneumologie 70(3):151–200CrossRefPubMed
11.
Zurück zum Zitat Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67(1):71–79CrossRefPubMed Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67(1):71–79CrossRefPubMed
12.
Zurück zum Zitat Baum H von, Welte T, Marre R et al (2010) Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 35(3):598–605CrossRef Baum H von, Welte T, Marre R et al (2010) Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 35(3):598–605CrossRef
13.
Zurück zum Zitat Drick N, Welte T (2016) Intensivpflichtige Virusinfektionen der unteren Atemwege. Intensivmed Up2date 12(2), DOI: 10.1055/s-0041-110072 (in press) Drick N, Welte T (2016) Intensivpflichtige Virusinfektionen der unteren Atemwege. Intensivmed Up2date 12(2), DOI: 10.1055/s-0041-110072 (in press)
14.
Zurück zum Zitat Postma DF, Werkhoven CH van, Elden LJ van et al (2015) Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372(14):1312–1323CrossRefPubMed Postma DF, Werkhoven CH van, Elden LJ van et al (2015) Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372(14):1312–1323CrossRefPubMed
15.
Zurück zum Zitat Garin N, Genné D, Carballo S et al (2014) β‑Lactam monotherapy vs β‑lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 174(12):1894–1901CrossRefPubMed Garin N, Genné D, Carballo S et al (2014) β‑Lactam monotherapy vs β‑lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 174(12):1894–1901CrossRefPubMed
16.
Zurück zum Zitat Jong E de, Oers JA van, Beishuizen A et al (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. doi:10.1016/S1473-3099(16)00053-0 Jong E de, Oers JA van, Beishuizen A et al (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. doi:10.1016/S1473-3099(16)00053-0
17.
Zurück zum Zitat Frat JP, Thille AW, Mercat A et al (2015) High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 372(23):2185–2196CrossRefPubMed Frat JP, Thille AW, Mercat A et al (2015) High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 372(23):2185–2196CrossRefPubMed
18.
Zurück zum Zitat Kreppein U, Litterst P, Westhoff M (2016) Hypercapnic respiratory failure: Pathophysiology, indications for mechanical ventilation and management. Med Klin Intensivmed Notfmed 111(3):196–201CrossRefPubMed Kreppein U, Litterst P, Westhoff M (2016) Hypercapnic respiratory failure: Pathophysiology, indications for mechanical ventilation and management. Med Klin Intensivmed Notfmed 111(3):196–201CrossRefPubMed
19.
Zurück zum Zitat Welte T (2016) Beatmungstherapie – eine Erfolgsgeschichte. Med Klin Intensivmed Notfmed 111(3):184–185CrossRefPubMed Welte T (2016) Beatmungstherapie – eine Erfolgsgeschichte. Med Klin Intensivmed Notfmed 111(3):184–185CrossRefPubMed
20.
Zurück zum Zitat Reinhart K, Brunkhorst FM, Bone HG et al (2010) Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI). Anaesthesist 59(4):347–370CrossRefPubMed Reinhart K, Brunkhorst FM, Bone HG et al (2010) Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI). Anaesthesist 59(4):347–370CrossRefPubMed
21.
Zurück zum Zitat Blum CA, Nigro N, Briel M et al (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385(9977):1511–1518CrossRefPubMed Blum CA, Nigro N, Briel M et al (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385(9977):1511–1518CrossRefPubMed
22.
Zurück zum Zitat Torres A, Sibila O, Ferrer M et al (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313(7):677–686 (Feb)CrossRefPubMed Torres A, Sibila O, Ferrer M et al (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313(7):677–686 (Feb)CrossRefPubMed
23.
Zurück zum Zitat Esperatti M, Ferrer M, Theessen A et al (2010) Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 182(12):1533–1539CrossRefPubMed Esperatti M, Ferrer M, Theessen A et al (2010) Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 182(12):1533–1539CrossRefPubMed
24.
Zurück zum Zitat Dalhoff K, Abele-Horn M, Andreas S et al (2012) Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. S‑3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy. Pneumologie 66(12):707–765CrossRefPubMed Dalhoff K, Abele-Horn M, Andreas S et al (2012) Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. S‑3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy. Pneumologie 66(12):707–765CrossRefPubMed
25.
Zurück zum Zitat Dalhoff K, Ewig S (2013) Guideline development group adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment. Dtsch Arztebl Int 110(38):634–640PubMedPubMedCentral Dalhoff K, Ewig S (2013) Guideline development group adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment. Dtsch Arztebl Int 110(38):634–640PubMedPubMedCentral
26.
Zurück zum Zitat American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388–416CrossRef American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388–416CrossRef
28.
Zurück zum Zitat Pletz MW, Wellinghausen N, Welte T (2011) Will polymerase chain reaction (PCR)-based diagnostics improve outcome in septic patients? A clinical view. Intensive Care Med 37(7):1069–1076CrossRefPubMed Pletz MW, Wellinghausen N, Welte T (2011) Will polymerase chain reaction (PCR)-based diagnostics improve outcome in septic patients? A clinical view. Intensive Care Med 37(7):1069–1076CrossRefPubMed
29.
Zurück zum Zitat Lugosi M, Alberti C, Zahar JR, Garrouste M, Lemiale V, Descorps-Desclère A, Ricard JD, Goldgran-Tolédano D, Cohen Y, Schwebel C, Vésin A, Timsit JF, Azoulay E (2014) Aspergillus in the lower respiratory tract of immunocompetent critically ill patients. J Infect 69(3):284–292CrossRefPubMed Lugosi M, Alberti C, Zahar JR, Garrouste M, Lemiale V, Descorps-Desclère A, Ricard JD, Goldgran-Tolédano D, Cohen Y, Schwebel C, Vésin A, Timsit JF, Azoulay E (2014) Aspergillus in the lower respiratory tract of immunocompetent critically ill patients. J Infect 69(3):284–292CrossRefPubMed
30.
Zurück zum Zitat Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van Wijngaerden E (2009) Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 35(9):1526–1531CrossRefPubMed Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van Wijngaerden E (2009) Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 35(9):1526–1531CrossRefPubMed
31.
Zurück zum Zitat Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589–1596CrossRefPubMed Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589–1596CrossRefPubMed
32.
Zurück zum Zitat Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, Artigas A, Schorr C, Levy MM (2014) Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 42(8):1749–1755CrossRefPubMed Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, Artigas A, Schorr C, Levy MM (2014) Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 42(8):1749–1755CrossRefPubMed
33.
Zurück zum Zitat Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A et al (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40(1):32–40CrossRefPubMed Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A et al (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40(1):32–40CrossRefPubMed
34.
Zurück zum Zitat Heyland DK, Dodek P, Muscedere J et al (2008) Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 36(3):737–744CrossRefPubMed Heyland DK, Dodek P, Muscedere J et al (2008) Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 36(3):737–744CrossRefPubMed
35.
Zurück zum Zitat Brunkhorst FM, Oppert M, Marx G et al (2012) Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 307(22):2390–2399CrossRefPubMed Brunkhorst FM, Oppert M, Marx G et al (2012) Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 307(22):2390–2399CrossRefPubMed
36.
Zurück zum Zitat Kaasch AJ, Rieg S, Kuetscher J et al (2013) Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. Infection 41(5):979–985CrossRefPubMed Kaasch AJ, Rieg S, Kuetscher J et al (2013) Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. Infection 41(5):979–985CrossRefPubMed
37.
Zurück zum Zitat Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54(5):621–629CrossRefPubMed Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54(5):621–629CrossRefPubMed
38.
Zurück zum Zitat Chastre J, Blasi F, Masterton RG et al (2014) European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 20(Suppl 4):19–36CrossRefPubMed Chastre J, Blasi F, Masterton RG et al (2014) European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 20(Suppl 4):19–36CrossRefPubMed
39.
Zurück zum Zitat Ramirez J, Dartois N, Gandjini H et al (2013) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57(4):1756–1762CrossRefPubMedPubMedCentral Ramirez J, Dartois N, Gandjini H et al (2013) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57(4):1756–1762CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Paul M, Bishara J, Yahav D et al (2015) Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 350:h2219CrossRefPubMedPubMedCentral Paul M, Bishara J, Yahav D et al (2015) Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 350:h2219CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Theuretzbacher U, Van Bambeke F, Cantón R (2015) Reviving old antibiotics. J Antimicrob Chemother 70(8):2177–2181CrossRefPubMed Theuretzbacher U, Van Bambeke F, Cantón R (2015) Reviving old antibiotics. J Antimicrob Chemother 70(8):2177–2181CrossRefPubMed
42.
Zurück zum Zitat Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TW, Sánchez AS, Zhou X, Saulay M, Engelhardt M (2014) A phase 3 randomized double-blind comparison of Ceftobiprole Medocaril versus Ceftazidime plus Linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 59(1):51–61CrossRefPubMedPubMedCentral Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TW, Sánchez AS, Zhou X, Saulay M, Engelhardt M (2014) A phase 3 randomized double-blind comparison of Ceftobiprole Medocaril versus Ceftazidime plus Linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 59(1):51–61CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Solé-Lleonart C, Rouby JJ, Chastre J et al (2016) Intratracheal administration of antimicrobial agents in mechanically ventilated adults: an international survey on delivery practices and safety. Respir Care. doi:10.4187/respcare.04519PubMed Solé-Lleonart C, Rouby JJ, Chastre J et al (2016) Intratracheal administration of antimicrobial agents in mechanically ventilated adults: an international survey on delivery practices and safety. Respir Care. doi:10.4187/respcare.04519PubMed
44.
Zurück zum Zitat Solé-Lleonart C, Roberts JA, Chastre J et al (2015) Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clin Microbiol Infect 22(4):359–364CrossRefPubMed Solé-Lleonart C, Roberts JA, Chastre J et al (2015) Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clin Microbiol Infect 22(4):359–364CrossRefPubMed
Metadaten
Titel
Die schwere Pneumonie auf der Intensivstation
verfasst von
Prof. Dr. T. Welte
Publikationsdatum
09.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Medizinische Klinik - Intensivmedizin und Notfallmedizin / Ausgabe 4/2016
Print ISSN: 2193-6218
Elektronische ISSN: 2193-6226
DOI
https://doi.org/10.1007/s00063-016-0165-9

Weitere Artikel der Ausgabe 4/2016

Medizinische Klinik - Intensivmedizin und Notfallmedizin 4/2016 Zur Ausgabe

Passend zum Thema

ANZEIGE

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

Das Niveau der postpandemischen Fallzahlen für invasive Pneumokokken-Erkrankungen (IPD) ist aus Sicht des Referenz-Zentrums für Streptokokken in Aachen alarmierend [1]. Wie sich die monatlichen IPD-Fallzahlen bei Kindern und Jugendlichen von Juli 2015 bis März 2023 entwickelt haben, lesen Sie hier.

ANZEIGE

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

ANZEIGE

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

MSD Sharp & Dohme GmbH